Advertisement


David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial

2016 Genitourinary Cancers Symposium

Advertisement

David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).



Related Videos

Solid Tumors

Nicholas D. James, BSc, MBBS, PhD, on Urothelial Carcinomas: Year in Review

Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.

Bladder Cancer

Srikala S. Sridhar, MD: Bladder Cancer Update

Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.

Kidney Cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version)

Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 499).

Solid Tumors

Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update

Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.

Prostate Cancer

W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).

Advertisement

Advertisement




Advertisement